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Abstract 
 
The concepts on the pathophysiology of intestinal fibrosis in Crohn’s disease (CD) have 
changed in recent years. Some years ago fibrosis was regarded to be a consequence of 
long standing inflammation with subsequent destruction of the gut wall matrix followed 
by scar formation and collagen deposition. Fibrosis in CD patients appeared to be an 
irreversible process that could hardly be influenced. Therefore, the main target in CD 
therapy was to control inflammation in order to avoid fibrosis development. Many of 
these assumption seem to be only partially true. Inflammation may be a necessary pre-
requisite for the initiation of fibrosis. However, when the pathophysiologic processes that 
lead to fibrosis in CD patients have been initiated fibrosis development may be 
independent of inflammation and may continue even when inflammation is under good 
medical control. Fibrosis in CD also may be reversible. After strictureplasty local collagen 
deposits decrease or even disappear. With new animal models for intestinal fibrosis on 
the horizon, we need to spend more efforts on understanding the factors influencing 
fibrosis in CD patients to finally find specific therapies. In this context it will be as 
important to find markers and quantitative imaging tools to have reliable endpoints for 
clinical trials in fibrosing CD. 
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Introduction 
Fibrosis in general can be characterized as exaggerated accumulation of collagen-rich 
extracellular matrix (ECM) in a tissue normally containing much less connective tissue 
with permanent or transient local expansion of mesenchymal cells or mesenchymal like 
cells  and subsequent impairment of organ function [1].  
Traditionally, fibrosis in CD has been seen as a relatively slow process needing many 
months to develop [2]. In the discussion of delayed diagnosis of CD it is usually 
emphasized that stricturing complications of CD and severe fibrosis of CD intestine could 
by avoided by a timely diagnosis [3]. However, recent data indicate that this may not 
necessarily be the case. A rapid development of fibrosis in some patients seems to be 
possible. Rapid re-occurrence of fibrosis has been described in patients that undergo liver 
transplantation for hepatic fibrosis or cirrhosis [4]. Rapid lung fibrosis could be induced 
by inhalative toxins in animal models [5; 6] and rapid liver fibrosis is seen in some models 
of primary sclerosing cholangitis [7]. These data and further evidence supports the 
concept that under certain circumstances fibrosis and subsequent stricture formation in 
some CD patients may be much faster than traditionally assumed. 
It is evident from clinical findings that fibrosis only develops in segments of the gut where 
inflammation in the context of CD is present [1]. Fibrosis in gut segments that never 
showed inflammatory involvement has not been reported. While this seems to be 
obvious, it is less clear what factors really trigger the process.  
Another “dogma” also has been revised recently. It is no longer believed that only primary 
mesenchymal cells such as fibroblasts or smooth muscle cells can contribute to fibrosis in 
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CD [1]. Cells that contribute to fibrosis in CD patients may also derive from intestinal 
epithelial cells via a process called epithelial to mesenchymal transition (EMT) [1; 2; 8; 9] 
or from endothelial cells via endothelial-to-mesenchymal transition (EndoMT) [10]. 
A third important new aspect in the discussion is the assumption that fibrosis in CD may 
not be irreversible [11; 12]. After strictureplasty in patients with CD suffering from clinical 
strictures the fibrosis in the gut wall was later on found to be reduced or even completely 
absent [13]. Reversibility of fibrosis had been demonstrated before in other fibrotic 
diseases such as liver fibrosis [14]. 
Intestinal fibrosis subsequently is neither necessarily a very slow process, nor completely 
dependent on the presence of inflammation, nor irreversible [1; 2; 9; 12; 15]. Therefore, 
it appears to be important to review the cellular and molecular factors that contribute to 
fibrogenesis in CD.  
 
Factors activating matrix producing cells 
Matrix-producing cells are activated by paracrine signals, autocrine factors, and 
pathogen-associated molecular patterns (PAMPs) derived from microorganisms or 
damage-associated molecular patterns (DAMPs) that interact with pattern recognition 
receptors (PRRs) [1; 2; 12; 15]. Transforming growth factor β (TGF-β) is an important 
mediator of mesenchymal cell activation. Its important role as a central regulator of 
fibrosis has been emphasized for many tissues and diseases [16; 17; 18; 19; 20; 21; 22; 
23; 24]. TGF-β expression is found to be upregulated in inflamed mucosa of inflammatory 
bowel disease (IBD) patients [25; 26; 27; 28]. In addition, also inhibitory molecules of TGF-
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β action such as SMAD7 are upregulated in CD mucosa [29; 30]. Recent therapeutic 
approaches now targets SMAD7 expression by an anti-sense oligonucleotide (Mongersen) 
to allow more TGF-β action mainly of regulatory T-cells [31]. It will be interesting to see 
whether a parallel activation of mesenchymal cells can be prevented [32]. Data on 
mesenchymal cell activation and collagen deposition derived from clinical trials that are 
under way with Mongersen will help us to understand which role TGF-β plays for the 
activation of mesenchymal cells, for the initiation of EMT or EndoMT and for gut wall 
fibrosis in CD patients. 
Other factors that play an important role in activating mesenchymal cells are activins [33], 
connective tissue growth factor (CTGF) [34; 35; 36], platelet-derived growth factor 
(PDGF), insulin-like growth factor (IGF-1, -2), epidermal growth factor (EGF), and 
endothelins (ET-1, -2, -3) [2; 12; 15]. All of those factors increase collagen synthesis by 
mesenchymal cells upon stimulation [2; 12; 15]. The relative contribution of the 
respective factors and whether synergies are developed is unclear. Therefore, it is also 
unclear whether targeting one of those factors in an anti-fibrotic therapeutic approach 
would make sense [1].   
Besides those specific factors inflammation per se is a strong activator of mesenchymal 
cells and also contributes to EMT and EndoMD [1; 8]. Therefore, it has been assumed by 
many authors that control of inflammation would prevent the development of gut wall 
fibrosis. This seems to be questionable now. Recent epidemiological data indicate that 
biologicals have reduced the number of surgeries performed due to insufficient control 
of inflammation. However, despite effective and much better control of inflammation the 
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development of CD in general from a B1 phenotype (only inflammatory) to a B2 (fibrotic) 
or B3 (penetrating) phenotype seems not to be significantly reduced [37; 38]. This raises 
the important questions whether inflammatory mediators and molecules trigger the 
fibrotic process early and whether this process finally becomes independent from 
inflammation. If this would be the case – and there is quite some evidence to support this 
assumption – the development of anti-fibrotic therapies would be absolutely mandatory. 
If we cannot interfere with the progression of fibrosis in a significant number of patients 
with our current therapeutic armamentarium, the need for new drug development 
becomes obvious. 
 
Animal models to study fibrosis-promoting factors and potential therapies 
Several animal models for the study of intestinal fibrosis have been proposed and 
described [1]. All of them have some advantages as well as disadvantages and none of 
them really resembles intestinal fibrosis of CD patients. Spontaneous intestinal fibrosis 
does not occur in rodent models and therefore all models require some manipulation and 
artificial conditions. 
The first models used to study intestinal fibrosis were models in which colonic 
inflammation was chemically induced, such as the trinitrobenzene-sulfonic acid (TNBS) 
and chronic dextran sodium sulfate (DSS) colitis in mice [1]. Some collagen deposition and 
fibrosis is observed in these models. However, fibrosis is usually inconsistent and the 
experimental duration until the occurrence of fibrosis limits the applicability of the 
mentioned mouse models. In addition, the contribution of the chemical trigger of the 
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inflammation (TNBS or DSS) raises some concerns with respect to pathophysiological 
relevance. Similar to those chemically triggered models, the injection of the bacterial-wall 
derived compound peptidoglycan-polysaccharide (PG-PS) into the gut wall induces 
inflammation and fibrosis [39]. While this model is an example for fibrosis triggered by 
microbial products, it is unclear whether bacteria play an essential role in CD fibrosis. The 
SAMP1/Yit mouse was reported to develop spontaneous inflammation with ileitis and 
fibrosis [40; 41]. However, the access to this model is limited and the extent of fibrosis 
seems to depend on the vivarium the mice are bred in.  
To be able to study therapeutic interventions with the target of inhibiting intestinal 
fibrosis we established a new – but still very artificial model. For the study of bronchiolitis 
obliterans and bronchial fibrosis pulmonologists had developed a heterotopic transplant 
model of trachea in rats [42]. We adopted this model and investigated whether the 
heterotopic transplantation of small intestine into the neck fold of rats would also be 
followed by the development of fibrosis. Indeed, we detected a rapid fibrosis of the small 
intestinal wall occurring within two weeks [43]. This was associated with increased 
expression of typical mediators of fibrosis such as αvβ6 integrin, IL-13, and TGF-β [43]. 
Further, we detected a loss of intestinal epithelium morphology, could demonstrate 
exaggerated collagen deposition, which led to luminal wall thickening culminating in a 
veritable fibrotic occlusion of the intestinal lumen [43]. As the available reagents to study 
fibrosis in rats are limited and it was desirably to study certain knock out or transgenic 
animal models we investigated whether the heterotopic transplant model also would 
work in mice (figure 1A-C). As expected, we found a similar time course of development 
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of fibrosis in the mouse model [44]. C57BL/6 are used as donors for isogeneic 
transplantation into C57BL/6 recipients in this model. Interestingly a rapid re-
vascularization occurs in the intestinal grafts in the neck fold (figure 1D-F). In small 
intestinal grafts isolated up to 21 days after transplantation the lumen was obstructed by 
granulation tissue and fibrotic material (figure 1G-J and [44]). The grafts partially had lost 
their typical crypt structure which in some specimen occurred already at day two after 
transplantation indicating that hypoxia may have an important role for this development. 
Collagen layer thickness was observed to be significantly increased  in grafts in a time-
dependent manner (figure 2A-B and [44]). Confirmatively Tgf-β and collagen mRNA was 
observed to be significantly increased in a time-dependent manner (figure 2C-E and [44]).  
We used this newly developed model to study established anti-fibrotic drugs and their 
effect on the development of fibrosis [44]. Pirfenidone so far is the best established 
therapy for idiopathic lung fibrosis [45; 46; 47]. When we applied pirfenidone three times 
a day for six days by oral gavage we found that the collagen layer was significantly 
decreased in comparison to the collagen layer thickness in grafts from vehicle treated 
mice [44]. Similar, TGF-β mRNA expression was significantly decreased upon pirfenidone 
treatment compared to vehicle [44].  
 
Factors involved in tissue remodeling 
Additional factors involved in intestinal fibrosis that have not been discussed so far 
regulate the turnover of the extracellular matrix (ECM) [2; 12; 15; 48]. It is generally 
assumed that in normal tissue i.e. in the normal intestinal wall there is a fine balance 
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between ECM production and degradation [1]. This balance is maintained on one hand by 
matrix metalloproteinases (MMPs) that break down and degrade ECM and on the other 
hand tissue inhibitors of matrix metalloproteinases (TIMPs) that counteract this 
degrading activity. Under pathophysiologic conditions, when ECM production is increased 
and surpasses degradation intestinal fibrosis will occur. In human CD strictures increased 
expression of MMPs and also TIMPS has been observed. However, it is difficult of course 
to functionally investigate the balance and dynamics between the different pro-degrading 
and degradation-inhibiting proteins and mechanisms.  
Further functions of MMP-9 include the regulation of cell migration, invasion, cell 
signaling as well as induction and regulation of EMT in multiple tissues [49; 50; 51]. In fact 
MMP-9 is the most abundantly expressed tissue degrading and re-modelling protease in 
inflamed CD tissue [52]. In biopsies from CD patients, MMP-9 was found as latent (pro-) 
and mature form [53]. Further, serum and urinary levels of MMP-9 correlate with disease 
activity in CD patients. It has been suggested that MMP-9 serum levels could be a useful 
marker of CD disease activity in children. In DSS colitis in mice targeted deletion of MMP-
9 has a protective effect, whereas mice overexpressing MMP-9 develop more severe 
colitis [53].  
As MMPs are obviously involved in intestinal fibrosis we determined the expression of 
tissue remodeling proteases MMP-2, -9, -13 and TIMP-1 in our heterotopic transplant 
model by real-time PCR. When mice were treated with pirfenidone a significant decrease 
in MMP-9 mRNA expression was observed [44]. Similar, MMP-2, -13 and TIMP-1 mRNA 
expression was decreased upon pirfenidone [44].   
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Further, we investigated, whether the therapeutic neutralization of MMP-9 by specific 
antibodies would alter the development of fibrosis in the heterotopic transplant model. 
When we treated mice in our model with two different anti-MMP-9 antibodies the lumen 
of the intestinal grafts was only partially obstructed and some crypt structures were still 
present [53]. Whereas the collagen layer was much thicker in grafts harvested from the 
isotype control-treated group, grafts harvested from anti-MMP-9 antibody-treated mice 
showed almost “normal” collagen layer thickness [53]. Treatment with the two anti-
MMP-9 antibodies was followed by lower accumulation of newly synthesized collagen, 
significantly thinner collagen layer and lower collagen-specific amino acid hydroxyproline. 
Expression of MMP-9 and TIMP-1 were not significantly changed by the MMP-9 antibody 
treatment [53]. When we assessed gelatinase activity in homogenates from our grafts by 
zymography and by ELISA all day-14 explants exhibited increased total MMP-9 and the 
MMP-9 antibody treatment was followed by some reduction of MMP-9 activity in the 
explants [53].  
 
Summary 
We have just started to more specifically understand the factors and pathways that lead 
to intestinal fibrosis. This is necessary to address the high clinical need of focused 
treatment of fibrosis in CD patients. New animal models may be helpful to screen for 
successful therapies. In some models such as the heterotopic transplant model of small 
intestinal segments pirfenidone and anti-MMP-9 antibodies have provided promising 
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results. Further studies will be necessary to confirm these results and to find additional 
factors promoting development of fibrosis in CD. 
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Figures 
 
Figure 1: Heterotopic transplantation, re-vacularization and luminal occlusion of the 
graft. (A) Small bowel resections are extracted from C57BL/6 mice. (B) For isogeneic 
transplantation the resection (arrow) is implanted into subcutaneous tissue in the 
neck of C57BL/6 mice. (C) The graft is freed from the pouch and harvested from the 
neck of the recipient 14 days post transplantation. (D - F) Grafts in the neck of 
recipient animals observed in situ present a decreased length but are otherwise 
macroscopically intact. Blood vessels from the surrounding tissue stretch towards 
the graft where they form a dense network (2 fold magnification). (G) Histologic 
cross sections of freshly isolated small intestine (day 0). Small bowel resections are 
extracted from C57BL/6 mice, implanted into C57BL/6 mice for isogeneic 
transplantation and explanted at day (H) 2, (I) 6 and (J) 14 after transplantation. 
Transmitted light microscopy, H&E staining. Grafts revealed luminal occlusion.  
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Figure 2: Collagen layer thickness and Tgf-β, Col1a1 and Col3a1 mRNA are significantly 
increased in grafts from the heterotopic transplantation model in a time-
dependent manner. Small bowel resections are extracted from RAG2 knockout 
mice and implanted into RAG2 knockout mice for isogeneic heterotopic 
transplantations. (A) Sirius Red staining. Transmission light microscopy and 
polarized light microscopy. (B) Collagen layer thickness measurement using 
transmission light microscopy confirmed significantly increased collagen layer 
thickness in a time-dependent manner (** p < 0.01, *** < 0.001, ANOVA, Dunn’s 
multiple comparison test). Thickness was calculated from at least eight places in 
representative areas at 10-fold magnification for each single graft. (C) Tgf-β qPCR. 
(D) Col1a1. (E) Col1a3. * p < 0.05, ** p < 0.01, Kruskal-Wallis test, Dunn’s multiple 
comparison test. 
 
